Chia Sin Eye Care-B (06622) announced that the board of directors expects the Group to achieve a maximum loss of RMB 77 million for the six months ending on June 30, 2024...
According to the announcement released by Chia Sin Eye Care-B (06622), the board of directors expects the Group to achieve a maximum loss of no more than RMB 77 million for the six months ending on June 30, 2024, while the maximum loss for the same period in 2023 was about RMB 0.234 billion.
The announcement stated that the expected reduction in losses during the period is mainly due to the milestone payment received by the company in the first half of 2024 under a product license agreement; the research and development expenses related to the two candidate drugs, NVK002 and TAB014, which will soon complete phase III clinical trials are expected to decrease; and the revenue from sales of ophthalmic drugs (including Betamethasone Sodium Phosphate and Rebamipide) for the six months ending on June 30, 2024 is expected to increase.
